Developments in post-marketing comparative effectiveness research - Wikidata - wikimedia - TriplyDB

Developments in post-marketing comparative effectiveness research

Developments in post-marketing comparative effectiveness research

http://www.wikidata.org/entity/Q34001867

about

Difficulties in demonstrating superiority of an antibiotic for multidrug-resistant bacteria in nonrandomized studies Disease risk score as a confounder summary method: systematic review and recommendations Clinical Comparative Effectiveness Research Through the Lens of Healthcare Decisionmakers A prescription for improving drug formulary decision making Utilization and comparative effectiveness of caspofungin and voriconazole early after market approval in the U.S Effectiveness of anti-psychotics and related drugs in the Huntington French-speaking group cohort "Threshold-crossing": A Useful Way to Establish the Counterfactual in Clinical Trials?Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research Learning About Missing Data Mechanisms in Electronic Health Records-based Research: A Survey-based Approach.Improving therapeutic effectiveness and safety through big healthcare data.Using secondary data sources for pharmacoepidemiology and outcomes research.Confounder summary scores when comparing the effects of multiple drug exposures Is aspirin useful in patients on lithium? A pharmacoepidemiological study related to bipolar disorder.Distinguishing Selection Bias and Confounding Bias in Comparative Effectiveness Research.Potential and pitfalls of using large administrative claims data to study the safety of osteoporosis therapies.Outpatient treatment in German adolescents with depression: an analysis of nationwide health insurance data.Hospital-activity data inaccurate for determining spread-of-disease at diagnosis for non-small cell lung cancer.Refilling and switching of antiepileptic drugs and seizure-related events Engineering practice variation through provider agreement: a cluster-randomized feasibility trial.Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study.Near-real-time monitoring of new drugs: an application comparing prasugrel versus clopidogrel.Accounting for unobservable exposure time bias when using Medicare prescription drug data.Real World Data in Adaptive Biomedical Innovation: A Framework for Generating Evidence Fit for Decision-Making.Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs Thirty-day complications after laparoscopic or open cholecystectomy: a population-based cohort study in Italy Different analyses estimate different parameters of the effect of erythropoietin stimulating agents on survival in end stage renal disease: a comparison of payment policy analysis, instrumental variables, and multiple imputation of potential outcome Academic centers play a vital role in the study of drug safety and effectiveness.Utilization of health care databases for pharmacoepidemiology.Some methodological points to consider when performing systematic reviews in comparative effectiveness research.The Nordic prescription databases as a resource for pharmacoepidemiological research--a literature review.Case-crossover study design in pharmacoepidemiology: systematic review and recommendations.Methods to control for unmeasured confounding in pharmacoepidemiology: an overview.The First Decade with the Swedish Prescribed Drug Register - A Systematic Review of the Output in the Scientific Literature.Assessment of Confounders in Comparative Effectiveness Studies From Secondary Databases.The intriguing future of pharmacoepidemiology.Population-based evaluation of the effectiveness of two regimens for emergency contraception.Association Between Preadmission Functional Status and Use and Effectiveness of Secondary Prevention Medications in Elderly Survivors of Acute Myocardial Infarction.Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors.Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery Angiotensin-converting enzyme inhibitor treatment and the development of urinary tract infections: a prescription sequence symmetry analysis.

P2860

Q26863059-B3F5A203-A4B9-440F-9968-85619D845A24 Q26999267-CDBB00CB-D876-4556-9374-CB703B51039F Q28085245-A65E00D5-A48F-4798-B71A-19E57EB2A199 Q28483879-5F53F627-08C9-46D4-86C2-5195FB2A004F Q28538618-EC9AE7C8-5F37-4744-9818-C879E72CA879 Q28538703-0265F4CA-50E9-43D8-81F1-8F7181283DCD Q28595570-D4A5FB0B-B4F9-4AEB-8C32-E983EBF9AE94 Q30419845-6989438E-824D-4D51-9C8B-0E961EE9C76F Q31008656-A6CA0049-F2C6-4377-BD3F-2B8DC64B7E80 Q31031741-A3840A27-FD72-42C8-9E57-B3C5F37DEC2C Q33403014-AA7E52B9-B56F-4ABA-A266-EB49C1B27E29 Q33566259-F56A1794-B6D3-4917-9CA1-7F18E7DF9EC9 Q33637566-4BED294D-426D-413D-A847-5364A3B18DA7 Q33707304-B6320479-1E8B-47A8-B5D8-8A6A0B6A4333 Q33818302-7E5EE13C-3B5E-4707-9C80-A174CE28FFC2 Q34283902-22216375-FDEC-4329-AD48-7E023945C9B0 Q34294069-1FA19DB4-9F19-4A09-AD08-17F6CC16DFAA Q34374193-AD0811C9-6E0E-4458-99A2-645FD6B42587 Q34446304-0185303C-EE68-46B3-95E8-EDA1B8CAF918 Q34490448-93C0C690-F2EE-4C69-B1CF-D886A97DF263 Q35089550-C4943567-0DFD-458A-8410-9BAAA78ABAE1 Q35169774-0EE08DD2-C1D9-4034-8136-11648C9E026E Q36132510-80174A51-7C77-4000-949B-892A3590EC03 Q36361147-598CE4FF-9445-4607-805E-EBFF6E220DEA Q36650258-B20D3FD1-8906-4149-AB89-8DBF8BD62FAC Q37019516-C12662A6-0021-4ADA-AD1F-7C98516B730E Q37734459-4D14D044-B9E4-4BA6-9927-E54BCCFD025B Q37910015-2B1C7B17-1A81-42EA-A960-EDFA6C3C5CC3 Q37952156-D3EC53A8-8D80-4837-A3E9-4DF2B12B1452 Q38109104-E628D35E-3ED8-46DD-8127-2A573B3B8D8F Q38137002-62926081-A023-452F-AF9A-8AD097711ADE Q38811363-0738EB99-6EBF-4EB0-A27E-03F5C76EF774 Q38817217-77F45BF1-15E6-444E-A456-7677FD49CCA7 Q38842054-CCB87481-7EBB-4D14-947C-1FF899A487ED Q39422831-2C1D9BA3-4379-4656-A0AC-B75F7F64D988 Q39927302-7C30258B-68D6-4421-A95E-AE85F2052A05 Q39958104-28597377-A5F7-4207-810F-DF489973B2AD Q40760702-E4179BBD-0CE6-4802-A427-5BCB3B322E30 Q42198767-9683D46A-E332-4FCE-9DD3-7D6B9D3369B6 Q43423190-8BD045B3-963A-4D20-89C9-37DB9BE41A11

P2860

Developments in post-marketing comparative effectiveness research

http://www.wikidata.org/entity/Q34001867

description

2007 nî lūn-bûn

@nan

2007 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Developments in post-marketing comparative effectiveness research

@ast

Developments in post-marketing comparative effectiveness research

@en

Developments in post-marketing comparative effectiveness research

@nl

type

label

Developments in post-marketing comparative effectiveness research

@ast

Developments in post-marketing comparative effectiveness research

@en

Developments in post-marketing comparative effectiveness research

@nl

prefLabel

Developments in post-marketing comparative effectiveness research

@ast

Developments in post-marketing comparative effectiveness research

@en

Developments in post-marketing comparative effectiveness research

@nl

P1433

Q34001867-4FCA0756-DB29-4F52-B24C-959B4D30FA15

P1476

Q34001867-F657494E-4566-4C86-BBC4-AE7438CB6222

P2093

Q34001867-ADF45CA0-68A6-4B56-97E7-378554F6F390

P2860

Q34001867-02DF5405-A011-40C4-A71D-F1168DEA735F

Q34001867-05102871-02CE-43F5-ADC4-27C5AC2D28FD

Q34001867-0784B928-EB97-483F-B106-B8AF0A0C51BA

Q34001867-08AB1739-4C9C-4456-BB3E-8F061758FCEF

Q34001867-0A4F5478-3819-4807-AFD0-B6F6B6E6CF7C

Q34001867-0BD64099-3536-40C2-8B60-E3D97D4BBA05

Q34001867-12997EE3-9DCE-44E8-8AEB-8AA2DF3AF7A3

Q34001867-13C4236C-4DC2-4A16-8578-248A18DE8CE3

Q34001867-1901131F-43C2-4733-9B40-9BDE445A60D3

Q34001867-1BFC5332-4AC6-47A9-BCBF-8D616A768E42

P304

Q34001867-03EC9376-1ED7-4930-A761-6DF9DDFA6846

P31

Q34001867-50A4FDF1-5D56-4BB2-987A-0CC242F68DCF

P356

Q34001867-C6648141-1D76-42AA-ABA5-5E4110E935EC

P407

Q34001867-298DD194-499C-4F86-ADDC-D9D83C6B2929

P433

Q34001867-8280BB94-9CF1-41CF-B045-6953C31DF231

P478

Q34001867-039B7DC2-18B6-4468-9E80-A8D1C4E75C15

P577

Q34001867-85EDEAF4-DE2C-4A5F-9DCF-B35B36F1369D

P5875

Q34001867-ABF1F3C4-5B67-4718-890E-F70418B8E59D

P698

Q34001867-8675498B-D029-41D1-90F8-FC96533C04CD

P932

Q34001867-57FF1483-8572-42BF-9CE8-E1C7B2E37ADC

P356

SJ.CLPT.6100249

P1433

Clinical Pharmacology & Therapeutics

P1476

Developments in post-marketing comparative effectiveness research

@en

P2093

S Schneeweiss

http://www.w3.org/2001/XMLSchema#string

P2860

Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports

Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction

Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis

Maternal pesticide exposure from multiple sources and selected congenital anomalies.

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Combination of direct and indirect evidence in mixed treatment comparisons

The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials

Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data.

Claims data studies of sedative-hypnotics and hip fractures in older people: exploring residual confounding using survey information.

Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration.

P304

143-156

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.CLPT.6100249

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

82

http://www.w3.org/2001/XMLSchema#string

P577

2007-06-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6283063

http://www.w3.org/2001/XMLSchema#string

P698

17554243

http://www.w3.org/2001/XMLSchema#string

P932

2905665

http://www.w3.org/2001/XMLSchema#string